Cargando…
Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses
INTRODUCTION: Systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD) represent pediatric and adult variants of the Still’s disease continuum. To determine whether clinical outcomes between patients with sJIA and AOSD were similar, Bayesian and population model-based ana...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964916/ https://www.ncbi.nlm.nih.gov/pubmed/35044647 http://dx.doi.org/10.1007/s40744-021-00422-9 |
_version_ | 1784678316248137728 |
---|---|
author | Dunger-Baldauf, Cornelia Nakasato, Priscila Noviello, Stephanie Whelan, Sarah Bieth, Bruno |
author_facet | Dunger-Baldauf, Cornelia Nakasato, Priscila Noviello, Stephanie Whelan, Sarah Bieth, Bruno |
author_sort | Dunger-Baldauf, Cornelia |
collection | PubMed |
description | INTRODUCTION: Systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD) represent pediatric and adult variants of the Still’s disease continuum. To determine whether clinical outcomes between patients with sJIA and AOSD were similar, Bayesian and population model-based analyses were conducted on endpoints from studies of canakinumab in both patient populations. The objective was to further support the efficacy of canakinumab in patients with AOSD. METHODS: A Bayesian analysis of endpoints from a study of canakinumab in AOSD was conducted borrowing information from five pooled sJIA studies using a robust meta-analytic predictive (MAP) approach. Similarity of clinical outcomes across populations was fulfilled if the AOSD study posterior median fell within the 95% predicted credible interval for the outcome of interest, based on the pooled sJIA data. Population model-based analyses (pharmacokinetic [PK] and PK/pharmacodynamic [PKPD]) were conducted to compare the pharmacokinetics and exposure–response relationships between populations. RESULTS: The AOSD study posterior medians for adapted American College of Rheumatology (ACR)30 response, continuous adapted ACR response, number of active joints, C-reactive protein, and absence of fever were within the 95% credible interval for the prediction of the MAP analysis from the pooled sJIA data, supporting the similarity in outcomes between patient populations. PK analysis demonstrated comparable exposure across sJIA age groups and patients with AOSD. PKPD relationships were consistent across patient populations. Analyses indicated that no therapeutic benefit can be expected from a dose increase in patients with AOSD. CONCLUSION: The analyses presented support the similarity of clinical outcomes following treatment with canakinumab in patients with sJIA and AOSD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40744-021-00422-9. |
format | Online Article Text |
id | pubmed-8964916 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-89649162022-04-12 Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses Dunger-Baldauf, Cornelia Nakasato, Priscila Noviello, Stephanie Whelan, Sarah Bieth, Bruno Rheumatol Ther Brief Report INTRODUCTION: Systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD) represent pediatric and adult variants of the Still’s disease continuum. To determine whether clinical outcomes between patients with sJIA and AOSD were similar, Bayesian and population model-based analyses were conducted on endpoints from studies of canakinumab in both patient populations. The objective was to further support the efficacy of canakinumab in patients with AOSD. METHODS: A Bayesian analysis of endpoints from a study of canakinumab in AOSD was conducted borrowing information from five pooled sJIA studies using a robust meta-analytic predictive (MAP) approach. Similarity of clinical outcomes across populations was fulfilled if the AOSD study posterior median fell within the 95% predicted credible interval for the outcome of interest, based on the pooled sJIA data. Population model-based analyses (pharmacokinetic [PK] and PK/pharmacodynamic [PKPD]) were conducted to compare the pharmacokinetics and exposure–response relationships between populations. RESULTS: The AOSD study posterior medians for adapted American College of Rheumatology (ACR)30 response, continuous adapted ACR response, number of active joints, C-reactive protein, and absence of fever were within the 95% credible interval for the prediction of the MAP analysis from the pooled sJIA data, supporting the similarity in outcomes between patient populations. PK analysis demonstrated comparable exposure across sJIA age groups and patients with AOSD. PKPD relationships were consistent across patient populations. Analyses indicated that no therapeutic benefit can be expected from a dose increase in patients with AOSD. CONCLUSION: The analyses presented support the similarity of clinical outcomes following treatment with canakinumab in patients with sJIA and AOSD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40744-021-00422-9. Springer Healthcare 2022-01-19 /pmc/articles/PMC8964916/ /pubmed/35044647 http://dx.doi.org/10.1007/s40744-021-00422-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Brief Report Dunger-Baldauf, Cornelia Nakasato, Priscila Noviello, Stephanie Whelan, Sarah Bieth, Bruno Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses |
title | Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses |
title_full | Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses |
title_fullStr | Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses |
title_full_unstemmed | Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses |
title_short | Similar Clinical Outcomes in Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease Treated with Canakinumab: Bayesian and Population Model-Based Analyses |
title_sort | similar clinical outcomes in patients with systemic juvenile idiopathic arthritis and adult-onset still’s disease treated with canakinumab: bayesian and population model-based analyses |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964916/ https://www.ncbi.nlm.nih.gov/pubmed/35044647 http://dx.doi.org/10.1007/s40744-021-00422-9 |
work_keys_str_mv | AT dungerbaldaufcornelia similarclinicaloutcomesinpatientswithsystemicjuvenileidiopathicarthritisandadultonsetstillsdiseasetreatedwithcanakinumabbayesianandpopulationmodelbasedanalyses AT nakasatopriscila similarclinicaloutcomesinpatientswithsystemicjuvenileidiopathicarthritisandadultonsetstillsdiseasetreatedwithcanakinumabbayesianandpopulationmodelbasedanalyses AT noviellostephanie similarclinicaloutcomesinpatientswithsystemicjuvenileidiopathicarthritisandadultonsetstillsdiseasetreatedwithcanakinumabbayesianandpopulationmodelbasedanalyses AT whelansarah similarclinicaloutcomesinpatientswithsystemicjuvenileidiopathicarthritisandadultonsetstillsdiseasetreatedwithcanakinumabbayesianandpopulationmodelbasedanalyses AT biethbruno similarclinicaloutcomesinpatientswithsystemicjuvenileidiopathicarthritisandadultonsetstillsdiseasetreatedwithcanakinumabbayesianandpopulationmodelbasedanalyses |